Insider Selling: BioLife Solutions (NASDAQ:BLFS) CFO Sells 990 Shares of Stock

BioLife Solutions, Inc. (NASDAQ:BLFS) CFO Troy Wichterman sold 990 shares of the stock in a transaction dated Tuesday, January 6th. The shares were sold at an average price of $25.59, for a total transaction of $25,334.10. Following the completion of the sale, the chief financial officer owned 150,746 shares of the company’s stock, valued at approximately $3,857,590.14. The trade was a 0.65% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Troy Wichterman also recently made the following trade(s):

• On Tuesday, December 9th, Troy Wichterman sold 1,033 shares of BioLife Solutions stock. The shares were sold at an average price of $25.13, for a total value of $25,959.29.
• On Thursday, December 4th, Troy Wichterman sold 30,000 shares of BioLife Solutions stock. The shares were sold at an average price of $25.72, for a total value of $771,600.00.
• On Tuesday, November 25th, Troy Wichterman sold 584 shares of BioLife Solutions stock. The stock was sold at an average price of $26.74, for a total transaction of $15,616.16.

BioLife Solutions Stock Down 1.8%

BioLife Solutions stock traded down $0.46 on Thursday, hitting $24.95. The company’s stock had a trading volume of 268,601 shares, compared to its average volume of 364,316. The firm has a market cap of $1.20 billion, a P/E ratio of -356.38 and a beta of 1.93. The company has a fifty day moving average price of $25.51 and a 200-day moving average price of $24.81. BioLife Solutions, Inc. has a one year low of $19.10 and a one year high of $29.62.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. Invesco Ltd. boosted its position in BioLife Solutions by 0.5% in the 3rd quarter. Invesco Ltd. now owns 3,599,444 shares of the medical equipment provider’s stock valued at $91,822,000 after buying an additional 18,666 shares during the last quarter. Vanguard Group Inc. boosted its holdings in BioLife Solutions by 2.4% in the third quarter. Vanguard Group Inc. now owns 2,967,518 shares of the medical equipment provider’s stock valued at $75,701,000 after acquiring an additional 70,248 shares during the last quarter. Ameriprise Financial Inc. boosted its holdings in BioLife Solutions by 11.3% in the second quarter. Ameriprise Financial Inc. now owns 1,080,371 shares of the medical equipment provider’s stock valued at $23,271,000 after acquiring an additional 109,959 shares during the last quarter. Dimensional Fund Advisors LP increased its position in BioLife Solutions by 2.1% in the third quarter. Dimensional Fund Advisors LP now owns 1,003,383 shares of the medical equipment provider’s stock worth $25,592,000 after purchasing an additional 20,175 shares during the period. Finally, Geode Capital Management LLC raised its holdings in BioLife Solutions by 3.8% during the 2nd quarter. Geode Capital Management LLC now owns 921,105 shares of the medical equipment provider’s stock worth $19,842,000 after purchasing an additional 33,849 shares during the last quarter. Institutional investors own 93.24% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts recently commented on the company. UBS Group reaffirmed a “buy” rating on shares of BioLife Solutions in a research note on Monday, December 29th. Wall Street Zen downgraded shares of BioLife Solutions from a “buy” rating to a “hold” rating in a research note on Sunday, November 30th. Zacks Research lowered shares of BioLife Solutions from a “strong-buy” rating to a “hold” rating in a report on Monday, December 8th. HC Wainwright reissued a “buy” rating and set a $32.00 price target on shares of BioLife Solutions in a report on Monday, December 29th. Finally, Northland Securities set a $34.00 price target on shares of BioLife Solutions in a research report on Monday. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $32.00.

About BioLife Solutions

BioLife Solutions (NASDAQ:BLFS) specializes in biopreservation and cold chain workflow solutions for cell and gene therapies, regenerative medicine and other advanced biologics. The company develops and markets proprietary cryopreservation media and technology platforms designed to maintain cell viability and functionality during processing, storage and transport. BioLife’s product portfolio addresses critical steps in the manufacturing and distribution of cell-based products, helping life science researchers and biopharmaceutical manufacturers protect and preserve living cells.

The company’s flagship offerings include CryoStor, a family of serum-free cryopreservation media; HypoThermosol, a hypothermic storage solution for short-term cell and tissue preservation; and the ThawSTAR system, an automated cell thawing instrument that delivers controlled and reproducible warming of frozen cell therapies.